Anti-Nerve Growth Factor Developers Face Go/No-Go Recommendation From Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA sets March 12 as date for the Arthritis Advisory Committee to weigh in on whether safety issues are a barrier to development of anti-NGF compounds as analgesics. Developers’ trials are on hold while FDA considers the potential for adverse effects seen in osteoarthritis patients taking the monoclonal antibodies for pain.